Stephan Brand is Vice President at SAP AG and responsible for the development and Go to Market of a innovative SAP solution targeting Enterprise Knowledge Discovery. Stephan Brand is with SAP since 1996 and served in various position in sales as well as in development in Europe and Asia Pacific. In addition, he was Assistant to the executive board. He holds a Master of Science in Industrial Engineering and Management.

Dan brings to Caprion Proteomics deep industrial experience in applying the CellCarta® proteomics platform to drug target and biomarker discovery. Prior to joining the Company, Dan was President and General Manager of BioSignal Packard Inc. (a division of Perkin Elmer), where he oversaw the development of novel technologies and reagents for drug discovery and genomics research, including the AlphaScreenTM and BRET2TM technologies and product lines. Dan also spent five years at Pharmacopeia where, as Senior Director of Biology, his team identified many lead compounds from Pharmacopeia’s million member combinatorial chemistry libraries that resulted in multiple compounds in the clinic. His previous experience also includes positions at Onyx Pharmaceuticals and the DuPont Merck Pharmaceutical Company in cancer research. Dan received his B.Sc. from the University of California at Santa Barbara and his Ph.D. in Chemistry from the University Of Oregon Institute of Molecular Biology and was an American Cancer Society fellow at the University of California at Berkeley.

Dr. Cronin’s current position is Vice President of Translational Research at Genomic Health, Inc.  There she heads a team responsible for conducting initial feasibility research for new product concepts encompassing both technical and biological aspects of each concept including laboratory processes, automation systems, and data management with bioinformatics and biostatistical analyses.   All product concepts are focused on applying genomic biomarkers to provide clinically relevant molecular pathology tests for patient and physician clients.  Programs focus on delivering high throughput, high-performance, innovative, first-in-class medical products in a regulated reference laboratory environment.  Dr. Cronin brings 20 years of R&D experience in biotechnology companies focused on applying cutting edge technology to clinical diagnostics including ACLARA BioSciences, Protogene Laboratories and, Affymetrix where she played a key role in developing DNA microarray (GeneChipä) technology.  Dr. Cronin’s Ph.D. in Molecular Pharmacology is from the University of California, San Diego and her undergraduate education from the University of California, Davis.

Dr. Dhar is Deloitte’s Chief Medical Informatics Officer. He helps clients develop innovative strategies to improve clinical outcomes and therapeutic discovery. His translational informatics work is helping clients discover new approaches to optimize clinical R&D with breakthrough information management approaches. He has been retained by numerous provider systems, Cancer Centers, Life Science companies and Governmental Agencies to define translational research programs. Dr. Dhar is also a Senior Fellow with the Deloitte Center for Health Solutions. He developed the Center’s perspective on the ROI for Personalized Medicine with the Personalized Medicine Coalition which was presented at the American Association for the Advancement of Science. Dr. Dhar has deep functional and management experience that spans public and private sector clients. He has provided senior leadership for numerous Electronic Health Record (EHR) implementations in the US, Canada, and the UK. He has also helped design enterprise data warehousing solutions, clinical discovery applications, and quality improvement programs at large integrated delivery networks and academic medical institutions. Dr. Dhar has a deep experience in developing clinical and research informatics programs. He is a Senior Advisor to the FDA’s Enterprise Architecture team. He also has provided biomedical informatics advisory services for the National Cancer Institute (NCI) and has served on multiple study sections for the NIH National Human Genome Research Institute. Dr. Dhar holds a Medical Degree from the University of Illinois, a Masters in Business Administration degree from the University Of Chicago Booth School Of Business, and a Bachelor in Arts degree from the University of Chicago.

Yael German Mayor Herzliya

Professor Eddy Karnieli is a graduate of the Rappaport Faculty of Medicine at the Technion– Israel Institute of Technology in Haifa.He obtained clinical training in Internal Medicine and Endocrinology at the Rambam Medical Center and did his Post-Doctoral Fellowship in Diabetes, Obesity and Endocrinology at the National Institutes of Health in Bethesda, Maryland.
He was a visiting scholar at the University of California at San Diego and at the National Institutes of Health. He is currently the Director of the Institute of Endocrinology, Diabetes and Metabolism at the Rambam Medical Center. Professor Karnieli's main research interests are the molecular mechanisms for regulating cellular glucose uptake and transporters and their implications in diabetes, obesity and insulin resistance; Gene therapy modalities to trans-differentiate human cells toward beta-cells as a potential cure for type 1 diabetes; Medical informatics, telemedicine and personalized medicine. He has published about 70 peer reviewed papers and reviews.Professor Karnieli serves on the editorial board of several scientific journals and review boards. Professor Karnieli is a retired Colonel from the Israel Defense Forces Medical Corps and is a former Deputy Director of the Rambam Medical Center.

Peter Kash is co-founder and President of Riverbank Capital Securities specializing in creating and financing biopharmaceutical companies. In his more than 20 year career he has co-founded more than a dozen companies and has co-raised over $800 million in private and public financings. He has served on several private and public boards both as Chairman and Vice-Chairman. Currently he serves as Chairman of Nile Therapeutics and sits on the board of Arno Therapeutics He has traveled and lectured in over 60 countries worldwide. Mr. Kash has worked on Wall Street for 25 years including at Shearson Lehman Hutton. From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo. He also served as Entrepreneur in Residence at Pace University and at Ball State University. In 2005-2006 he was a Professor at the Sy Syms School of Business. He has frequently lectured and served as a Key Note Speaker around the world, from Australia, Singapore, Egypt, to Russia and at such prestigious academic centers as: Princeton, Harvard/MIT, Technion, IDC, Recanati School of Business at Tel Aviv University and Monash University in Melbourne, Australia. His education includes a BS in Management Science from SUNY- Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He recently completed his Doctorate studies in Education at The Azrieli Graduate School of Yeshiva University; currently completing his Thesis. He also completed post graduate classes on Making Board’s of Directors (both Profit and Non-for Profit) More Effective at Harvard Business School. He sits on several Non-for-profit Boards both in Israel and the United States. He has authored several books including ReStart, Make Your Own Luck and Freedom From Disease. Available in Hebrew as well.

David Sidransky, M.D. was appointed the Chairman of the Board of Directors in October, 2007. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is the Chairman of Alfacell Corporation and serves on the Board of Directors of Xenomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky serves as Director (2005-2008) of American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research. Dr. Sidransky received a B.A. from Brandeis University and M.D. from the Baylor College of Medicine.

Jayson Slotnik Health Policy Specialist Foley Hoag

Jayson Slotnik serves as Counsel in the firm’s Government Strategies practice, where he advises clients on Medicare and Medicaid coverage, as well as reimbursement and coding issues covering medical devices, diagnostic tests, drugs, and biologics. Prior to joining Foley Hoag LLP, he worked as an Associate for other nationally renowned law firms advising both payors and innovators pertaining to Medicare and Medicaid payment and coverage issues. Previously, Jayson served as the initial Director of Medicare and Medicaid Reimbursement at the Biotechnology Industry Organization (BIO), the principal trade organization for the global biotech industry, handling matters relating to insurance coverage, coding and payment of drugs and biologics. He regularly represented the industry before the Center for Medicare and Medicaid Services, as well as Congress regarding coverage and reimbursement issues. In addition, Jayson advised BIO members on business development issues and worked with the membership and affiliate groups to develop innovator friendly policies related to complex diagnostic tests and other medical therapies. Prior to law school, Jayson gained extensive private sector healthcare experience. He worked as an epidemiologist designing scientific studies demonstrating clinical effectiveness of client products. As a senior analyst for a legislative firm, he monitored Medicaid and Medicare programs for healthcare technology clients with an eye towards expanding access to clients' therapies. He started his career as a reimbursement analyst for a pharmaceutical consulting firm counseling pharmaceutical and biotechnology companies on Medicare, Medicaid and other government reimbursement policies.

Lior Soussan-Gutman, Ph.D. Director Advantest/Oncotest-TEVA, Teva Pharmaceuticals

Dr. Lior Soussan-Gutman, Director of Advantest/Oncotest-TEVA business unit in Teva Pharmaceuticals Inc. The unit provides an extended basket of services in clinical oncology, cardiovascular diseases and diabetes designed to tailor treatment to the unique characteristics of both patients and their disease. Dr. Soussan-Gutman was the founder and CEO of Oncotest Ltd., a company offering specialized cancer diagnostic service to the oncology community based on a network of laboratories around the world. Dr. Soussan-Gutman founded Oncotest Ltd. in 1998 and in 2003 Oncotest's activities were purchased by Teva Pharmaceutical Industries in Israel and became the Oncotest-Teva service unit, managed by Dr. Lior Soussan-Gutman. 2007 saw the extension of Oncotest-Teva's activity to additional sectors, becoming a part of ADVANTEST, with activity focusing on hereditary syndromes (risk assessment); Early Detection; Treatment Optimization; and Pharmacogenetics. Dr. Soussan-Gutman holds a Ph.D. in Neurobiochemistry from the Tel-Aviv University and she did Post-doctorate research in molecular biology at the Weizmann Institute of Science.

Keith Strier Principal & Partner, Health Sciences & Government Practice Deloitte LLP

Keith Strier is a Principal/Partner with Health Sciences & Government Practice of Deloitte LLP and serves in numerous roles including Co-Leader, Health Informatics and Senior Fellow in Deloitte’s Washington, DC-based healthcare think tank, Center for Health Solutions. Keith advises Ministries of Health and Multi-National Corporations alike on biomedical innovation, personalized healthcare, translational medicine and globalization themes such as medical tourism and cross-border collaboration. Keith has been a Guest Faculty at the Harvard Medical School / MIT Health Science Technology Program, lecturing on healthcare innovation, since 2002. He also serves as a Strategic Advisor to Harvard Medical School’s Center for BioMedical Informatics. Keith has been a guest speaker at many prominent US academic institutions, including UCLA’s LA BioMedical Research Institute, UC Irvine’s Healthcare MBA Program, USC’s Global BioBusiness Initiative, UC Berkeley’s BioExec Institute, Claremont’s Keck School of Applied Sciences and at the Mayo Clinic’s Inaugural Symposium on Innovation in Healthcare. Internationally, Keith has been an invited speaker at the Summit on Information Systems in Translational Research at Seoul National University in Seoul, South Korea (2008), at Peking Union Medical Center in Beijing, China (2009) and at Amgen’s 2nd annual Oncology and Hematology Conference in Istanbul, Turkey (2010). Mr. Strier has a Bachelor’s of Science in Industrial & Labor Relations with Honors from Cornell University (1993) and a Law Degree from New York University’s School of Law (1996).

Mr. Galil, a graduate of the Technion - Israel Institute of Technology and Purdue University in the USA was the founder of Elron Electronic Industries Ltd., and served as Chief Executive Officer of the company from 1962-1999. In 1999, Uzia Galil founded Uzia Initiatives and Management Ltd. and is presently the Chairman and Chief Executive Officer of the company, with the mission of helping regional innovations to become a global success by leveraging the experience and the global network of its management team and its partners worldwide. Uzia Galil has been awarded Honorary Doctorate degrees from Technion, The Weizman Institute of Science, Polytechnic University New York, Ben Gurion University, Solomon Bublick Prize Laureate from the Hebrew University of Jerusalem and Outstanding Electrical and Computer Engineer Award by the Purdue University, USA and the Israel Innovation Award). In 1997 he was awarded the prestigious Israel Prize for his contribution to the development of the Israel hi-tech industry.

Uzia Galil was one of the first to realize that the implementation of the "Personalized Medicine" for the benefit of the patient, requires strong corporation between the Bio-Medical and Genetic research and the advanced Computer and Bioinformatics to provide the adequate tools for the physician. This became the main purpose of the Galil Medical Center, which he founded, by leveraging interdisciplinary projects. Click here for full biography.

Shai Yarkoni brings a unique blend of life sciences experience, combining medical practice (Israeli Board-certified Ob/Gyn) and science (cellular and molecular biology) with executive management at various biotech start-up companies and international co development ventures. Dr. Yarkoni presently has founded and currently acts as the director General of BioNegev, an Israeli Innovation cluster founded to expedite the establishment of the Israeli life science industry. Concomitantly Dr. Yarkoni heads G.A.S.R Biotechnologies, a Biotech company dedicated to restarting promising Biotech ventures that failed due to non technological reasons. G.A.S.R holds commercializing rights of projects and IP that have raised >$15M in the past.  Prior to that, Dr Yarkoni served as the CEO of Target-In (fusion proteins for targeted cell suicide) and CTO of Collgard Biopharmaceuticals (small-molecule with anti fibrotic and anti angiogenic activity). In both companies Dr. Yarkoni and his teams developed the drug candidates from the academic bench to human clinical trials in USA, EU, UK and Israel.
Previously Dr. Yarkoni served for 10 years on the faculty of the Ob-Gyn dept. at the Sackler School of medicine in Tel-Aviv University, concomitantly founding and leading the Onco-Genetic service and Research Unit at the Sapir Medical Center, Israel.
Dr. Yarkoni has been involved in a number of international biotech activities, including a leading a co-development team with Boston Scientific from USA as well as Century Pharmaceuticals from India, the Steering Committee of a FP6 sponsored European Research Consortium (AMIS), as chair of the Healthcare Sector Advisory Committee to the Israel Export and international collaborations Institute, as a member of the Council of European BioRegions (CEBR) and Dr. Yarkoni holds MD and PhD degrees from the Hebrew University of Jerusalem, he published over 40 papers in peer review journals and holds 14 issued patents.

Until recently, Dr. Barzilay was the interim CEO of CollabRx, a biotechnology company whose goal is to help oncologists develop customized therapies for cancer patients who are unresponsive to standard treatments.  Dr. Barzilay is a Venture Consultant and was a General Partner with Walden International, a global Venture Capital firm with over $2 billion under management. At Walden Dr. Barzilay led several investments in innovative software companies and served on their boards. Prior to joining Walden Dr. Barzilay was Vice President & General Manager, Content and Supplier Solutions in Commerce One. Dr. Barzilay joined Commerce One as part of Commerce One's acquisition of Mergent Systems in January 2000. Dr. Barzilay was a co-founder, chairman, and CEO of Mergent Systems, a business-to-business e-commerce infrastructure start-up. Prior to Mergent, Dr. Barzilay held a variety of senior management positions including General Manager of C*ATS,  senior marketing executive at Informix and CEO at Syntelligence Systems. Prior to Syntelligence, Dr. Barzilay was an AI researcher at Xerox Parc. Dr. Barzilay has an engineering degree from the Technion in Israel and an M.B.A. and Ph.D. degree from the University of Pittsburgh.